Modelling and simulation in the development and use of anti-cancer agents: an underused tool?
To help identify the role of modelling and simulation in the development of anti-cancer agents, their main advantages and the obstacles to their rational use, an expert meeting was organized by COST B15. This manuscript presents a synthesis of views expressed at that meeting and indicates future directions. The manuscript also shows some examples where modelling and simulation have proven to be of relevant value in the drug development process for anti-cancer agents.
Rombout
Ferdinand
F
Department for Modelling and Simulation, Grünenthal GmbH, P.O. Box 500444, 52088 Aachen, Germany.
Aarons
Leon
L
Karlsson
Mats
M
Man
Anthony
A
Mentré
France
F
Nygren
Peter
P
Racine
Amy
A
Schaefer
Hans
H
Steimer
Jean-Louis
JL
Troconiz
Iñaki
I
van Peer
Achiel
A
D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D000069287:Capecitabine; D002986:Clinical Trials as Topic; D003198:Computer Simulation; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077143:Docetaxel; D004334:Drug Administration Schedule; D015195:Drug Design; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans; D008954:Models, Biological; D011358:Product Surveillance, Postmarketing; D011788:Quality of Life; D043823:Taxoids / Q000627:therapeutic use; D014747:Vinblastine / Q000031:analogs & derivatives / Q000627:therapeutic use
D000970:Antineoplastic Agents; D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; C111217:vinflunine; D014747:Vinblastine; D000069287:Capecitabine; D005472:Fluorouracil